Certifi, Inc’s Post

Financial hurdles, including rising deductibles and out-of-pocket costs, affect patients with cancer disproportionately. Many are often forced to choose between necessary treatments and financial stability. In cancer care, value-based care allows for reduced out-of-pocket expenses for life-saving treatments like immunotherapy, ensuring that patients are not burdened by unnecessary financial strain for vital therapies. #VBC #ValueBasedCare #Healthcare

I am pleased to share the Wisconsin Policy Forum "Picture of Health?" report supported by Lutheran Social Services of WI & Upper MI along with the American Cancer Society Cancer Action Network (ACS CAN), The Leukemia & Lymphoma Society, Community Care Services, Jewish Family Services, and the Wisconsin Medical Society. The report discusses Medicaid history and its current and potential impact, and options for future expansion in #Wisconsin which take into consideration the lessons learned from other states. Check out the report's findings and let me know how you would answer the question, Should Wisconsin expand Medicaid under the Affordable Care Act? https://lnkd.in/gdUZhmbP #SocialServices #Health

A topic that is becoming increasingly important in our lives: 𝚝𝚑𝚎 𝚊𝚍𝚟𝚊𝚗𝚌𝚎𝚖𝚎𝚗𝚝𝚜 𝚒𝚗 𝚖𝚎𝚍𝚒𝚌𝚊𝚕 𝚝𝚎𝚌𝚑𝚗𝚘𝚕𝚘𝚐𝚢, 𝚜𝚙𝚎𝚌𝚒𝚏𝚒𝚌𝚊𝚕𝚕𝚢 𝚙𝚛𝚎𝚌𝚒𝚜𝚒𝚘𝚗 𝚖𝚎𝚍𝚒𝚌𝚒𝚗𝚎, 𝚊𝚗𝚍 𝚒𝚝𝚜 𝚒𝚖𝚙𝚕𝚒𝚌𝚊𝚝𝚒𝚘𝚗𝚜 𝚘𝚗 𝚘𝚞𝚛 𝚏𝚒𝚗𝚊𝚗𝚌𝚒𝚊𝚕 𝚙𝚕𝚊𝚗𝚗𝚒𝚗𝚐.  This article delves into how precision medicine is revolutionising cancer treatments BUT at a steep cost. 🔍 Key Points: 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲: This innovative approach tailors treatments based on individual genetic profiles, significantly improving outcomes for cancer patients. 𝗥𝗶𝘀𝗶𝗻𝗴 𝗖𝗼𝘀𝘁𝘀: The sophistication of these treatments 𝘭𝘦𝘢𝘥𝘴 𝘵𝘰 𝘩𝘪𝘨𝘩𝘦𝘳 𝘤𝘰𝘴𝘵𝘴, which might not be fully covered by hospital plans 𝗜𝗺𝗽𝗮𝗰𝘁 𝗼𝗻 𝗜𝗻𝘀𝘂𝗿𝗮𝗻𝗰𝗲: With ongoing advancements in medical technology and treatments, the list of drugs covered under hospital plans is constantly evolving Why Should You Care?: Understanding the financial implications of these medical advancements is critical.  Hospital plans are indispensable, covering a significant portion of large medical bills. 𝙃𝙤𝙬𝙚𝙫𝙚𝙧, 𝙩𝙝𝙚𝙮 𝙤𝙛𝙩𝙚𝙣 𝙙𝙤 𝙣𝙤𝙩 𝙥𝙧𝙤𝙫𝙞𝙙𝙚 𝙥𝙖𝙮𝙤𝙪𝙩𝙨 𝙛𝙤𝙧 𝙞𝙣𝙘𝙤𝙢𝙚 𝙧𝙚𝙥𝙡𝙖𝙘𝙚𝙢𝙚𝙣𝙩 𝙙𝙪𝙧𝙞𝙣𝙜 𝙡𝙤𝙣𝙜-𝙩𝙚𝙧𝙢 𝙞𝙡𝙡𝙣𝙚𝙨𝙨𝙚𝙨, nor do they cover all new treatments. ⚠️ 𝐈𝐟 𝐲𝐨𝐮 𝐰𝐞𝐫𝐞 𝐮𝐧𝐚𝐛𝐥𝐞 𝐭𝐨 𝐰𝐨𝐫𝐤 𝐝𝐮𝐞 𝐭𝐨 𝐢𝐥𝐥𝐧𝐞𝐬𝐬, 𝐡𝐨𝐰 𝐰𝐨𝐮𝐥𝐝 𝐲𝐨𝐮 𝐦𝐚𝐧𝐚𝐠𝐞 𝐲𝐨𝐮𝐫 𝐝𝐚𝐲-𝐭𝐨-𝐝𝐚𝐲 𝐞𝐱𝐩𝐞𝐧𝐬𝐞𝐬 𝐚𝐧𝐝 𝐟𝐚𝐦𝐢𝐥𝐲 𝐜𝐨𝐦𝐦𝐢𝐭𝐦𝐞𝐧𝐭𝐬? ⚠️ 𝐀𝐫𝐞 𝐲𝐨𝐮 𝐩𝐫𝐞𝐩𝐚𝐫𝐞𝐝 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐟𝐢𝐧𝐚𝐧𝐜𝐢𝐚𝐥 𝐢𝐦𝐩𝐚𝐜𝐭 𝐨𝐟 𝐧𝐞𝐞𝐝𝐢𝐧𝐠 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭𝐬 𝐧𝐨𝐭 𝐜𝐨𝐯𝐞𝐫𝐞𝐝 𝐛𝐲 𝐲𝐨𝐮𝐫 𝐡𝐨𝐬𝐩𝐢𝐭𝐚𝐥 𝐩𝐥𝐚𝐧? ✅ 𝗥𝗲𝘃𝗶𝗲𝘄 𝗬𝗼𝘂𝗿 𝗖𝗼𝘃𝗲𝗿𝗮𝗴𝗲: It's crucial to ensure your health insurance matches your potential needs, especially with the rapid advancements in medical treatments. ✅ 𝗜𝗻𝗰𝗹𝘂𝗱𝗲 𝗜𝗻𝗰𝗼𝗺𝗲 𝗣𝗿𝗼𝘁𝗲𝗰𝘁𝗶𝗼𝗻: Adding income replacement insurance can safeguard your financial health against the unpredictability of long-term illness. ✅ 𝗦𝘁𝗮𝘆 𝗜𝗻𝗳𝗼𝗿𝗺𝗲𝗱: Keep updated with changes in your insurance policy and what it means for treatments like precision medicine. 𝐈𝐟 𝐲𝐨𝐮 𝐨𝐧𝐥𝐲 𝐡𝐚𝐯𝐞 𝐚 𝐡𝐨𝐬𝐩𝐢𝐭𝐚𝐥 𝐩𝐥𝐚𝐧 𝐚𝐧𝐝 𝐚𝐫𝐞 𝐜𝐨𝐧𝐜𝐞𝐫𝐧𝐞𝐝 𝐚𝐛𝐨𝐮𝐭 𝐠𝐚𝐩𝐬 𝐢𝐧 𝐲𝐨𝐮𝐫 𝐜𝐨𝐯𝐞𝐫𝐚𝐠𝐞, 𝐞𝐬𝐩𝐞𝐜𝐢𝐚𝐥𝐥𝐲 𝐟𝐨𝐫 𝐧𝐞𝐰 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭𝐬 𝐚𝐧𝐝 𝐢𝐧𝐜𝐨𝐦𝐞 𝐫𝐞𝐩𝐥𝐚𝐜𝐞𝐦𝐞𝐧𝐭, 𝐈 𝐞𝐧𝐜𝐨𝐮𝐫𝐚𝐠𝐞 𝐲𝐨𝐮 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 𝐨𝐮𝐭 📲 We can ensure your insurance strategy is comprehensive and tailored to meet both today’s needs and tomorrow’s challenges. https://lnkd.in/gZ-7aZZU

Some deeper analysis on how AI can help make public health accessible to a larger population. Let me know your thoughts and more ideas….

In a paper published in JCO Oncology Practice the following question was posted to clinicians: "How much does knowledge of the patient's insurance influence your decision to obtain the testing?" Almost half of the doctors, 47%, said this is a very significant factor, meaning if the insurance doesn't cover it, perhaps they won't order the test even though it might be lifesaving. While this paper was published in 2017, as Maurie Markman, MD from City of Hope points out in this Medscape commentary, it remains a critical question today and is becoming even more important everyday as new targeted and tumor agnostic therapies become available. It's time for #genomic4all. Learn more at https://hubs.ly/Q02GCRKy0 https://hubs.ly/Q02GCpgx0

Clover Health has announced that its #AI-powered clinical decision-making tool, Clover Assistant, will now be available to payers and providers as a Software-as-a-Service (#SaaS) under the new name Counterpart Assistant. This move aims to expand the tool's reach and improve healthcare outcomes across the board. Key Highlights: ✅ 37% of members saw better blood pressure control ✅ 21% were more likely to have a colorectal screening ✅ 12% were more likely to have a breast cancer screening CEO Andrew Toy shared insights on this shift during the Bank of America Healthcare conference, emphasizing the potential for wider adoption and the benefits of a hybrid SaaS and shared-savings model. This new approach could lead to lower customer acquisition costs and a unified tool for all Medicare Advantage patients. #HealthcareInnovation #AIinHealthcare #DigitalHealth #HealthTech

We've been featured in GenomeWeb's Year in Review article, which outlines that polygenic risk scores (PRS) are ready for clinical adoption, as several studies published in 2024 demonstrated the clinical utility and feasibility of implementing PRS into clinical workflows. The article features our successful trial with NHS England with GPs, which showed that Genomic Prevention fits in standard GP workflows, was very popular with patients, and that the approach both changed the management of a significant number of patients, as well as evolved the nature of the GP - patient conversation about prevention. The piece also covers our partnership with Mass Mutual Life Insurance Company. Our Health Insights product, available in the US, provides individuals with personalised information about their risk for seven common diseases, with advice on steps the individual can take to reduce their risk, and a report they can pass on to their doctors. This is done in a way that the life insurance company does not know which of their policyholders have taken the test, and doesn’t see the genetic results, or the individual reports. At Genomics, over the course of this year, we have advanced PRS applications across life sciences, health insurance, health systems, and employers. Watch this space for more to come in 2025! 🚀 #NHS #PRS #genomics #preventativehealthcare #health

Yale School of Medicine: #Telehealth Is Just as Effective as In-Person Care A multi-site study involving 1,250 patients with advanced lung cancer across 22 U.S. sites has found that those who received early palliative care via telehealth reported quality-of-life scores that were equivalent to those who received in-person care. The findings highlight the importance of keeping telehealth #accessible to patients and adds to growing evidence that telehealth provides comparable quality of care to in-person visits across specialties. https://lnkd.in/g_vhAnA6

A new study at CHR is testing an alternative to the Pap test for cervical cancer screening. CHR Investigator Amanda Petrik's new study, Self-Testing for Cervical Cancer in Priority Populations—the STEP-2 Trial, funded by the National Cancer Institute (NCI), seeks to increase cervical cancer screening rates in safety net clinics. Nearly 30 million people in the U.S. get their health care in clinics like these, which provide care to patients regardless of ability to pay or health insurance. About 90% of patients who get their care in safety net clinics are low-income, and about 64% are members of racial and ethnic minority groups. Read more here: https://lnkd.in/g4grW9mi

I'm sorry, what? This article in the NYT about practices telling patients about the option to have their mammograms "read" by artificial intelligence--and the musings about whether practices will pay for this or if it'll be on patients to foot the bill. (I mean, is it going to show up as a line item or something to opt out of?) I wonder how many of us as patients realize that AI can and is being used to help detect cancers already? And you know what, the more I reflect on it, the framing of this article bothers me: AI can help radiologists detect patterns and find things that may not be visible to the human eye (even that of a skilled mammographer). It's about how this story is positioned in terms of cost to patients, which bugs me given all the recent coverage--and our experience as patients with health insurance who are always astounded as to what isn't covered, regardless of how high our premiums go.